{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"180","value":"140"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"title":"Cycle 1 Day 1, 0.5-4 h Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"136","value":"283"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 1, 6-10 h Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"61.4","value":"93.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 15, Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"256","value":"335"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"title":"Cycle 1 Day 15, 2-12 h Post-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"60.9","value":"67.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"44"}],"units":"Participants"}],"title":"Cycle 2 Day 1, Pre-dose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"127","value":"153"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Cycle 2 Day 1, 0.5-4 h"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"132","value":"278"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"}],"units":"Participants"}],"title":"Cycle 2 Day 1, 6-10 h"}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"}],"units":"Participants"}],"description":"PK samples were collected and analyzed using a population PK approach to estimate PK parameters. Individual predicted plasma concentration of lenvatinib was then derived from the PK model.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with Endometrial cancer (EC) received lenvatinib 20 milligrams (mg) orally, once daily, plus pembrolizumab 200 mg intravenously, every 3 weeks in each 21-day cycle. Participants continued to receive treatment until disease progression, development of unacceptable toxicity, withdrawal of consent, completion of 35 treatments (approximately 2 years) with pembrolizumab, or sponsor termination of the study","id":"OG000","title":"Lenvatinib 20 mg + Pembrolizumab 200 mg"}],"paramType":"MEAN","populationDescription":"Analysis population included all participants who have received at least 1 dose of study treatment with documented dosing history in the lenvatinib plus pembrolizumab arm and have measurable plasma levels of lenvatinib. Data is reported for pMMR participants. Here \"overall number of participants analyzed\" signifies participants who were evaluable for this outcome measure and \"number analyzed\" signifies participants evaluable at specific timepoints.","reportingStatus":"POSTED","timeFrame":"Cycle 1 day 1 0.5-4 hour (h), 6-10 postdose; Cycle 1 day 15 predose; Cycle 1 day 15 2-12h postdose, Cycle 2 day 1 predose, 0.5-4h, 6-10 h (Each cycle is 21 days)","title":"Plasma Concentration of Lenvatinib Versus Time in pMMR Participants","type":"SECONDARY","unitOfMeasure":"ng/mL"}